The Medical Technology Stock Letter (MTSL) provides solid investment advice based on company and industry fundamentals. Our thirty years of experience in providing investment advice for this unique and volatile sector gives MTSL and YOU the edge.
Our insistence on thorough research and knowledge of the forces moving the sector minimize your downside risk while maximizing your potential for capital growth. You won’t pay a fortune for MTSL either.
We’re making fresh company recommendations and providing more timely updates on breaking news than in the past. It’s not a change in investment philosophy—buying carefully selected biotech stocks and holding them long-term still promises the greatest return. But with more companies on our radar screen, a dynamic analyst team, and recommendations for long-term buying and short-selling stocks, there’s a lot to the new MTSL.
Get your sample issue today, or if you are already convinced, subscribe now: